二、前10名无限售条件股东持股情况 数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.3900 | 0.1900 | 105.26 | 0.6300 | | 每股净资产（元） | 18.24 | 25.45 | -28.33 | 14.24 | | 每股公积金(元) | 13.25 | 18.88 | -29.82 | 8.21 | | 每股未分配利润(元) | 3.47 | 4.92 | -29.47 | 4.50 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.76 | 1.24 | 41.94 | 2.14 | | 净利润(亿元) | 0.47 | 0.17 | 176.47 | 0.41 | | 净资产收益率(%) | 2.18 | 0.77 | 183.12 | 4.52 | | 名称 | 持有数量(万股) | 占总股本比 | 增减情 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥176,343,757.34, representing a 41.83% increase compared to ¥124,332,621.75 in the same period last year[4] - Net profit attributable to shareholders was ¥47,417,837.41, a significant increase of 183.24% from ¥16,741,205.71 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥42,553,380.50, up 171.28% from ¥15,686,119.75 in the previous year[4] - The basic and diluted earnings per share both increased by 105.26% to ¥0.39 from ¥0.19[4] - Total operating revenue for the current period reached ¥176,343,757.34, a 42% increase from ¥124,332,621.75 in the previous period[20] - Net profit for the current period was ¥47,417,837.41, compared to ¥16,741,205.71 in the previous period, representing a 183% increase[21] - Basic and diluted earnings per share increased to ¥0.39 from ¥0.19, marking a 105% rise[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,313,499,980.56, a 2.21% increase from ¥2,263,389,145.02 at the end of the previous year[4] - Current assets totaled RMB 1,579,764,504.34, up from RMB 1,503,877,958.89, indicating an increase of about 5.5%[17] - Total liabilities stood at RMB 116,704,446.63, slightly up from RMB 114,569,854.99, showing a marginal increase of about 1.9%[18] - The total equity attributable to the parent company reached RMB 2,196,795,533.93, compared to RMB 2,148,819,290.03 at the beginning of the period, reflecting an increase of approximately 2.2%[19] Cash Flow - The company's cash flow from operating activities decreased by 37.98% to ¥46,227,892.04 from ¥74,538,568.94 in the same period last year[4] - Operating cash flow net amount was ¥46,227,892.04, down from ¥74,538,568.94 in the previous period, indicating a decrease of 38%[23] - Cash and cash equivalents at the end of the period totaled ¥239,990,036.73, down from ¥536,014,618.49, a decline of 55%[23] - Investment activities generated a net cash flow of ¥2,528,001.29, a significant recovery from a net outflow of ¥21,447,108.10 in the previous period[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,778[10] - Kingchem (China) held 48.66% of the shares, making it the largest shareholder[11] - The total number of restricted shares at the end of the period was 63,705,741, with no changes during the reporting period[14] Expenses - Total operating costs amounted to ¥125,403,640.07, up from ¥110,839,890.09, reflecting a 13% increase[20] - The company's inventory decreased to RMB 175,026,165.78 from RMB 194,971,270.02, indicating a decline of about 10.3%[17] - The non-current assets totaled RMB 733,735,476.22, down from RMB 759,511,186.13, representing a decrease of approximately 3.4%[18] - The company's retained earnings increased to RMB 417,881,637.49 from RMB 370,607,655.09, reflecting a growth of about 12.7%[19] - The company reported a decrease in sales expenses to ¥4,899,774.21 from ¥5,094,051.33, a reduction of 4%[20] - Research and development expenses slightly increased to ¥7,018,049.89 from ¥6,964,404.48, reflecting a growth of 1%[20] Investment Income - The company reported a 111.52% increase in investment income to ¥3,377,328.16, compared to ¥1,596,683.03 in the previous year[9] Other Comprehensive Income - Other comprehensive income after tax showed a loss of ¥512,035.25 compared to a gain of ¥264,604.89 in the previous period[21]

CRO概念股盘初下挫，双成药业（002693）跌停，万邦医药（301520）跌超5%，谱尼测试 （300887）、新天地（301277）、金凯生科（301509）跟跌。 ...

Group 1 - The stock of Jinkai Biological Science (301509) closed at 26.71 yuan, with a decline of 6.87%, currently in a state of breaking issue [1] - Jinkai Biological Science was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on August 3, 2023, with an issuance of 21,508,335 shares, accounting for 25.00% of the total shares post-issuance, at a price of 56.56 yuan per share [1] - The total amount raised from the issuance was 1,216.5114 million yuan, with a net amount of approximately 1,110.7443 million yuan after deducting issuance costs, exceeding the original plan by 310.7443 million yuan [1] Group 2 - The company plans to use the raised funds for pharmaceutical intermediates, a project for producing 190 tons of high-end pharmaceutical products, and to supplement working capital [1] - The total issuance costs (excluding VAT) amounted to 105.7671 million yuan, with CITIC Securities receiving 86.5456 million yuan as underwriting and sponsorship fees [1] - The actual controllers of Jinkai Biological Science are FUMINWANG and LIANPINGWU, both holding U.S. nationality [1] Group 3 - The company's 2023 annual equity distribution plan includes a cash dividend of 8.00 yuan for every 10 shares and a capital reserve increase of 4.00 shares for every 10 shares [2] - The record date for the equity distribution is set for May 8, 2024, with the ex-dividend date on May 9, 2024 [2]

深交所上市公司定期现场检查报告 | 保荐人名称：中信建投证券股份有限公司 上市公司简称：金凯生科 | | | | | --- | --- | --- | --- | | 保荐代表人姓名：逯金才 联系电话：010-5605 2488 | | | | | 保荐代表人姓名：张林 联系电话：010-5605 1430 | | | | | 现场检查人员姓名：逯金才 | | | | | 现场检查对应期间：2024 年度 | | | | | 现场检查时间：2025 年 4 月 7 日-4 月 8 日 | | | | | 一、现场检查事项 | | 现场检查意见 | | | （一）公司治理 | 是 | 否 | 不适用 | | 现场检查手段（包括但不限于本指引第三十三条所列）：查阅公司章程、公司治理制度以及股东会、 | | | | | 董事会会议资料、信息披露文件等 | | | | | 1.公司章程和公司治理制度是否完备、合规 | √ | | | | 2.公司章程和股东会、董事会规则是否得到有效执行 | √ | | | | 3.股东会、董事会会议记录是否完整，时间、地点、出席 | √ | | | | 人员及会议内容等要件是否齐备 ...

暗盘资金流向曝光！提前捕捉庄家建仓信号>> 减肥药概念盘初活跃，金凯生科（301509）涨超10%，昊帆生物（301393）、华东医药（000963）、翰 宇药业（300199）、百花医药（600721）、一品红（300723）、常山药业（300255）等跟涨。消息面 上，礼来口服减肥药Orforglipron三期临床数据亮眼，股价涨逾14%。 ...

权益变动比例触及1%的公告 股东启鹭（厦门）股权投资合伙企业（有限合伙）、蓝色经济区产业投资基 金（有限合伙）、青岛青松创业投资集团有限公司－青岛松凯创业投资企业（有 限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 证券代码：301509 证券简称：金凯生科 公告编号：2025-003 金凯（辽宁）生命科技股份有限公司 关于股东减持期间届满及持股5%以上股东 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 公司于近日分别收到股东启鹭（厦门）股权投资合伙企业（有限合伙）（以下简 称"启鹭投资"）、蓝色经济区产业投资基金（有限合伙）（以下简称"蓝区基 金"）、青岛青松创业投资集团有限公司－青岛松凯创业投资企业（有限合伙）（以 下简称"青松投资"）提交的减持计划相关进展《告知函》，截至本报告披露日，前 述股东本次减持计划期限届满，其中启鹭投资股份变动比例触及1%。现将有关情况公 告如下： 一、股东减持情况 （一）启鹭投资 1、减持股份来源：首次公开发行前持有的公司股份（含该等股份上市后资本公 积金转增股本取得的股份）。 | 股东名称 | 减持方式 | ...

证券代码：301509 证券简称：金凯生科 公告编号：2025-002 近日，公司收到启鹭投资送达的《关于持有金凯（辽宁）生命科技股份有限公司 股份权益变动比例触及1%的告知函》，截至2025年2月14日，启鹭投资通过集中竞价方 式累计减持公司股份864,300股，占公司总股本的0.72%；通过大宗交易方式减持公司 股份1,204,500股，占公司总股本的1.00%；合计减持公司股份2,068,800股。本次权益 变动后，启鹭投资持有公司股份8,431,200股，占公司总股本比例由8.72%降至7.00%。 现将相关情况公告如下： | 1.基本情况 | | | --- | --- | | 信息披露义务人 | 启鹭（厦门）股权投资合伙企业（有限合伙） | | 住所 | 厦门市湖里区金山街道云顶北路16号308单元A389 | | 权益变动时间 | 2024年12月18日至2025年2月14日 | 1 | 金凯生科 股票简称 | 301509 股票代码 | | | | | --- | --- | --- | --- | --- | | 变动类型（可多选） 增加□ 减少☑ | 一致行动人 有□ 无☑ | | | | ...

Financial Performance Outlook - The company expects a net profit attributable to shareholders of between 38 million and 45 million CNY for 2024, representing a decline of 74.07% to 78.11% compared to the previous year's profit of 173.57 million CNY[2] - The net profit after deducting non-recurring gains and losses is projected to be between 17 million and 24 million CNY, indicating a decrease of 85.70% to 89.87% from last year's profit of 167.84 million CNY[2] Factors Affecting Performance - The significant decline in performance is attributed to reduced orders in the pharmaceutical business due to international trade environment factors and fluctuations in orders from major clients[4]

证券代码：301509 证券简称：金凯生科 公告编号：2024-040 金凯（辽宁）生命科技股份有限公司 关于公司股东减持股份的预披露公告 股东启鹭（厦门）股权投资合伙企业（有限合伙）、蓝色经济区产业投资基 金（有限合伙）、青岛青松创业投资集团有限公司－青岛松凯创业投资企业（有 限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 公司股东蓝色经济区产业投资基金（有限合伙）（以下简称"蓝区基金"）持有公 司股份5,507,476股（占公司总股本比例4.57%）。蓝区基金计划通过集中竞价和大宗交 易方式减持公司股份不超过3,612,000股（占公司总股本比例3%）。其中，通过集中竞 价方式减持的不超过1,204,000股，减持比例不超过公司总股本的1%，通过大宗交易方 式减持的不超过2,408,000股，减持比例不超过公司总股本的2%。集中竞价的减持期间 为自本减持计划公告之日起十五个交易日后的三个月内，大宗交易的减持期间为自本减 持计划公告之日起三个交易日后的三个月内。 公司股东青岛青松创业投资集团有限公 ...